Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products, which resulted in an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Issues - During the relevant period, RxSight promoted strong sales of its LAL and Light Delivery Device (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - On July 8, 2025, the company further lowered its revenue forecast, attributing it to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of LifeMD, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submis ...

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud impacting investors between February 26, 2025, and August 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management made misleading statements about the company's growth while concealing adverse facts, particularly regarding the health of its CEO, which affected the company's ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and lowered its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in C3.ai during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Quantum Corporation is facing significant financial difficulties and legal challenges, raising concerns among investors and market analysts regarding its stability and future prospects [1][4]. Financial Performance - Quantum reported an earnings per share (EPS) of -$1.85, which is significantly below the expected EPS of -$0.15, indicating substantial losses [5]. - The company's revenue was $59.7 million, falling short of the estimated $70.1 million, further highlighting its financial struggles [5]. - Quantum has a negative price-to-earnings (P/E) ratio of -0.34, indicating ongoing losses and investor skepticism [2][5]. - The price-to-sales ratio stands at 0.19, suggesting the stock is valued at 19 cents for every dollar of sales [2]. - The enterprise value to sales ratio is 0.62, reflecting a low total valuation relative to its sales [2]. Financial Ratios - Quantum's negative earnings yield of -2.98% indicates that the company is not generating positive returns for its shareholders [3]. - The debt-to-equity ratio of -0.81 suggests that Quantum has more liabilities than equity, raising concerns about its financial stability [3][5]. - The current ratio of 0.40 points to potential liquidity challenges in meeting short-term obligations [3]. Legal Issues - Quantum is facing a class action lawsuit initiated by The Rosen Law Firm, alleging securities fraud against investors who purchased QMCO securities between March 10, 2021, and April 15, 2025 [4][5]. - The Law Offices of Frank R. Cruz are also urging QMCO investors to explore potential securities fraud claims, indicating possible misconduct or misleading information affecting the stock [4].

Contact Us To Participate or Learn More: If you wish tolearn moreabout this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected]Call us at: 310-914-5007Visit our website at: www.frankcruzlaw.comFollow us for updates on Twitter: twitter.com/FRC_LAW. If you inquire by email, please include your mailing address, telephone number, and number of shares purc ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3]. Financial Performance and Issues - The company previously reported strong sales of LAL and Light Delivery Devices (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulting in another 38% drop in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether PubMatic and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until October 20, 2025, to request to be appointed as Lead Plaintiff if they purchased PubMatic securities during the Class Period [2]. Group 2: Financial Performance and Market Reaction - On August 11, 2025, PubMatic announced its financial results for Q2 2025, indicating a reduction in ad spend from a top demand side platform (DSP) partner [4]. - The CEO of PubMatic stated that a significant number of clients had shifted to a new platform, causing challenges in inventory valuation [4]. - Following this announcement, PubMatic's stock price fell by $2.23 per share, or 21.1%, closing at $8.34 per share on August 12, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by October 28, 2025 [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Semler and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Semler securities during the Class Period are advised to contact Pomerantz LLP to potentially become Lead Plaintiffs [2]. Group 2: Financial and Legal Context - On February 28, 2025, Semler disclosed a risk of a civil False Claims Act lawsuit from the U.S. Department of Justice regarding its QuantaFlo device, following an initial civil investigative demand received in July 2017 [4]. - Semler participated in unsuccessful settlement discussions with the DOJ in February 2025 [4]. - Following the announcement of the DOJ's involvement, Semler's stock price fell by $4.03 (9.4%) to close at $38.89 on March 3, 2025 [5]. - On April 15, 2025, Semler announced a settlement agreement with the DOJ for $29.75 million, leading to a further stock price decline of $3.40 (9.88%) to close at $31.00 on April 16, 2025 [5].

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud that negatively impacted investors between February 26, 2025, and August 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management made misleading statements about the company's growth while concealing adverse facts, particularly regarding the health of its CEO, which affected the company's ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and lowered its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in C3.ai during the specified timeframe have until October 21, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]